AOD-9604
Research profile · How we handle evidence
A piece of growth hormone designed just for fat burning. It helps break down fat without affecting blood sugar or causing muscle growth side effects. Very safe profile - FDA gave it GRAS status for a reason.
Evidence Score
High confidence
Category
Therapeutic area
Standard Dose
Once daily on empty stomach
Half-life
Plasma elimination
Route
Subcutaneous
Safety Tier
Well characterized
Overview
Scientists took the fat-burning piece of growth hormone and isolated it. That's AOD-9604. It burns fat without the other effects of GH. No blood sugar issues, no weird growth, no water retention. Just pure fat loss. Great if you're sensitive to other fat loss compounds.
Mechanism of Action
Fragment of growth hormone (residues 176-191) that stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or IGF-1 levels.
pH & Mixing
Peptides reconstituted at very different pH levels can destabilize when combined in the same syringe, which lowers how much of the peptide your body actually absorbs. If you're unsure whether two peptides are close enough in pH, reconstitute and inject them separately.
A dedicated compatibility check between two specific peptides is coming to the Compare tool. This section covers this peptide's pH only.
Benefits
- Burns fat without other GH side effects
- Stops your body from storing new fat
- Does not affect blood sugar or insulin
- May help with cartilage repair
- Very safe - GRAS status
Side Effects
- Minimal side effects overall
- Well-tolerated by most people
- Occasional injection site irritation
Contraindications
- Pregnant or breastfeeding women
- Individuals under 18 years old
- Those with known allergies to peptide components
Structure & Sequence
Verified structure
AOD-9604
Sequence illustration backed by PubChem match.
- Amino Acid Sequence
- YLRIVQCRSVEGSCGF (16aa, hGH 176-191 fragment with N-terminal Tyr)
- Molecular Weight
- 1,815.1 Da
- Chemical Formula
- C78H123N23O23S2
- CAS Number
- 158861-67-7
- Reconstituted pH
- 8.2
- InChIKey
- GVIYUKXRXPXMQM-BPXGDYAESA-N
Stack & Route Context
Stacks with
- BPC-157
- Ipamorelin
Administration
Subcutaneous
Research Status
FDA GRAS status. TGA approved in Australia for osteoarthritis. Well-studied for fat loss applications with excellent safety record.
Approval Status
Approved
Sports Legal
Permitted
References
- 1View source
AOD9604: a novel anti-obesity compound
2001
- 2
Effects of AOD9604 on adipose tissue
2004
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.